Changes in hepatitis C viral load during first 14days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy

Hepatology Research

Volumn 41, Issue 3, 2011, Pages 217-224

  Itakura, Jun ^a   Asahina, Yasuhiro ^a   Tamaki, Nobuharu ^a   Hirayama, Itsuko ^a   Yasui, Yutaka ^a   Tanaka, Tomohiro ^a   Sato, Mitsuaki ^a   Ueda, Ken ^a   Kuzuya, Teiji ^a   Tsuchiya, Kaoru ^a   Nakanishi, Hiroyuki ^a   Kurosaki, Masayuki ^a   Gabriel, Gretchen S ^b   Schneider, George J ^b   Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b Abbott Molecular Inc   (United States)

Author keywords

Hepatitis C; Interferon; Kinetics; Real time polymerase chain reaction; Undetectable time point

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RNA ANALYSIS; VIRUS LOAD;

EID: 79951799596     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00768.x     Document Type: Article

References (18)

1. Glue P, Rouzier-Panis R, Raffanel C etal.; The Hepatitis C Intervention Therapy Group. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000; 32: 647-53.
2. Reddy KR, Wright TL, Pockros PJ etal. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-8.
3. Sánchez-Tapias JM, Diago M etal.; TeraViC-4 Study Group. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-60.
4. Tsubota A, Chayama K, Ikeda K etal. Factors predictive of response to interferon- therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94.
5. Chayama K, Tsubota A, Kobayashi M etal. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 1997; 25: 745-9.
6. Enomoto N, Sakuma I, Asahina Y etal. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
7. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994; 21: 1-3.
8. Asahina Y, Izumi N, Hirayama I etal. Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. Gastroenterology 2008; 134: 1396-405.
9. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26: 1640-5.
10. Lee WM, Reddy KR, Tong MJ etal. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group. Hepatology 1998; 28: 1411-5.
11. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
12. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008; 46: 78-84.
13. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
14. Neumann AU, Lam NP, Dahari H etal. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-7.
15. Powers KA, Dixit NM, Ribeiro RM, Golia P, Talal AH, Perelson AS. Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis 2003; 23 (Suppl 1): 13-8.
16. Halfon P, Bourlière M, Pénaranda G, Khiri H, Ouzan D. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. J Clin Microbiol 2006; 44: 2507-11.
17. Gelderblom HC, Menting S, Beld MG. Clinical performance of the new rRoche COBAS TaqMan HCV Test and High Pure System for extraction, detection and quantitation of HCV RNA in plasma and serum. Antivir Ther 2006; 11: 95-103.
18. Berg T, Wagner MV, Nasser S etal. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-97.